The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
September 13th 2023
The European Medicines Agency has validated its Type II variation for enzalutamide as an option in patients with nonmetastatic hormone-sensitive prostate cancer at high risk of biochemical recurrence who are not suitable for salvage radiotherapy.
25th Annual International Lung Cancer Congress®
Register Now!
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
Register Now!
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
23rd Annual International Congress on the Future of Breast Cancer® West
Register Now!
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections™: Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board
View More
Dr Ravi on the Use of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
August 18th 2023Praful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.
Copper 64 PSMA I&T Meets Coprimary End Points of SOLAR Trial in Metastatic Prostate Cancer
August 15th 2023Use of Copper 64 PSMA I&T for PET/CT imaging met the threshold for significance regarding region-level correct localization rate and patient-level correct detection rate in patients with histologically confirmed metastatic prostate cancer, meeting the coprimary end points of the phase 2 SOLAR trial.
FDA Approves Niraparib Plus Abiraterone Acetate for BRCA+ mCRPC
August 11th 2023The FDA has approved niraparib plus abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive, metastatic castration-resistant prostate cancer, as detected by an FDA-approved test.
FDA Allows Continuation of Phase 1/2 Trial of ONCT-534 in mCRPC
August 11th 2023The FDA has approved a study may proceed letter in advance of its 30-day review period to Oncternal Therapeutics for its phase 1/2 study evaluating ONCT-534, a novel dual-action AR inhibitor in patients with mCRPC who have relapsed or are refractory to approved AR signaling inhibitors.
Lack of Clinical Benefit Leads to End of Development for Etrumadenant in mCRPC
The development of etrumadenant as a potential treatment option for patients with metastatic castration-resistant prostate cancer will be discontinued after data from the phase 1/2 ARC-6 trial did not demonstrate a sufficient clinical benefit for etrumadenant plus zimberelimab and docetaxel compared with docetaxel alone.
Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC
August 8th 2023Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.
Dr Sieber on the Importance of Evaluating Comorbidities in Prostate Cancer Prior to ADT
August 3rd 2023Paul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.
Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate
July 31st 2023Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.
Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC
July 26th 2023Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Varied levels of compliance were observed in terms of using validated quality indicators to determine the quality of active surveillance for patients with low-risk prostate cancer, according to findings from a population-based study published in the Journal of the Comprehensive Cancer Network.
NCCN Adds Flotufolastat F 18 Injection to Clinical Practice Guidelines for Prostate Cancer
The National Comprehensive Cancer Network has added flotufolastat F 18 injection to its Clinical Practice Guidelines in Oncology for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy.
FDA Awards Fast Track Designation to ARX517 for Metastatic Castration-Resistant Prostate Cancer
The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.
Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.
Dr Lowentritt on the Rationale for Investigating Real-World PSA Response to AR Inhibitors in mCSPC
July 18th 2023Benjamin H. Lowentritt, MD, FACS, discusses the background and rationale for conducting a real-world retrospective study of prostate-specific antigen responses generated from second-generation androgen receptor inhibitors in patients with metastatic castration-sensitive prostate cancer.
Dr Lowentritt on the Implications of Data on Real-World ASRI Efficacy in mCSPC
July 13th 2023Benjamin H. Lowentritt, MD, FACS, discusses how results from a real-world retrospective study of responses with second-generation androgen receptor signaling inhibitors in patients with mCSPC could affect the selection and use of next-generation ARSIs in practice, and how this research identifies several other unanswered questions for future investigation.
Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer
July 10th 2023Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.
Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC
The addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared with standard of care alone for patients with metastatic castration-resistant prostate cancer.
Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC
July 6th 2023Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
PSCA-Targeted CAR T-Cell Therapy Demonstrates Safety, Anticancer Activity in mCRPC
The use of prostate stem cell antigen–targeted CAR T-cell therapy was well tolerated and produced evidence of anticancer effects in patients with metastatic castration-resistant prostate cancer.